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ABSTRACT 
 
MADELINE GRIFFIN: Synthesis of Aromatic Fluorinated Ketones for Evaluation at the 
GABA Receptor 
(Under the direction of David A. Colby) 
GABA is a neurotransmitter that inhibits the excitation of neurons. Targeting this 
specific receptor has the potential to inhibit the central nervous system and possibly treat 
addiction, anxiety, or mood disorders. Previous research has shown that fluorinated 
ketones can have valuable applications in the medicinal chemistry of addiction. Some 
fluorinated ketones have shown activity at the GABA receptor. The main goal of this 
project was to synthesize aromatic fluorinated ketones for biological evaluation at the 
GABAB receptor. Another goal was to compare both the monofluorinated and 
difluorinated analogues synthesized in order to quantify differences in activity from 
fluorination state. New fluorinated agonists for the GABAB receptor present potential for 
pharmacological development because of the distinct structure in comparison to other 
GABA analogues. These compounds may assist in overcoming some of the current 
limitations in drug discovery at the GABAB receptor and are to be submitted for 
biological evaluation. 
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1. Introduction 
1.1 Neurotransmitter Signaling within the Central Nervous System 
The central nervous system in the human body is composed of the brain and the 
spinal cord. Within the brain, there are chemical compounds known as neurotransmitters. 
The brain uses neurotransmitters as chemical messengers to communicate throughout the 
nervous system and between individual brain cells, or neurons. The small distance 
between two individual neurons is known as the synapse or synaptic cleft. The first 
neuron that releases a neurotransmitter into the synaptic cleft is referred to as the 
presynaptic neuron. After it is released, a neurotransmitter can either be received by 
another neuron, taken back up into the presynaptic neuron, or broken down within the 
cleft. The neuron that receives the chemical messenger is referred to as the postsynaptic 
neuron.  
The postsynaptic neuron contains receptors for various messengers. When a 
neurotransmitter binds to a receptor, the receptor is activated leading to increased or 
reduced transmission of a particular signal. Excitatory neurotransmitters activate 
receptors to continue or increase signals, while inhibitory neurotransmitters activate 
receptors to decrease or cease signals from firing. The balance of inhibitory and 
excitatory signals within the brain is a major intrinsic regulatory mechanism for 
numerous physiological processes. 
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1.2 The Role of GABA in the Body 
GABA stands for 𝛾-aminobutyric acid (Figure 1). GABA is the primary inhibitory 
neurotransmitter. Inhibitory neurotransmitters can stop an action potential from 
depolarizing a postsynaptic neuron and can also inhibit the release of other excitatory 
neurotransmitters such as dopamine, serotonin, noradrenaline, and acetylcholine. The 
main function of GABA is to regulate the excitation of neurons and release of other 
neurotransmitters.1 
                                                 Figure 1 Structure of GABA 
GABA has two main receptors, GABAA and GABAB.. These two receptors are 
structurally and functionally unique. The GABAA receptor is an ionotropic receptor, or an 
ion channel-linked receptor. When the receptor is activated, the ion channel opens and 
there is an influx of chloride ions into the cell, causing the cell to become hyperpolarized 
and leading to reduced transmission of the signal. The GABAB receptor is a metabotropic 
receptor, or G-protein coupled receptor. G-protein coupled receptors, or GPCRs, can 
inhibit the release of many neurotransmitters. These receptors inhibit the activation of 
calcium (Ca2+) voltage-gated ion channels via a G-protein dependent process, inhibit 
adenylyl cyclase activity, and act on potassium (K+) channels.2 Most GABA-related 
pharmaceuticals target specifically the GABAA receptor, while there are few that are 
selective to the GABAB receptor except for baclofen (Figure 2), a commonly used muscle 
relaxant.2 
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1.3 Addiction Epidemic and Potential Treatment Strategies 
Addiction is a complex disease state that affects millions of lives across the world. 
With that fact and the recent opioid crisis in the United States, there is a push to find new 
treatment options for those that are suffering. One reason that the research conducted in 
this project focuses on the GABA receptor is to exploit the major inhibitory effects that 
accompany GABA in the CNS. By developing agonists, or substances that activate a 
receptor and increase the activity of that receptor, there is potential to reduce anxiety in 
patients that are suffering from addiction as well as cravings and symptoms of 
withdrawal.  
Some GABA agonists have been investigated for use in the treatment of 
addiction, alcoholism, and addiction-related processes such as anxiety, pain, and 
depression.3 The FDA approved drug, baclofen, which is also a GABAB agonist, has been 
used “off-label” for the treatment of opioid addiction.4,5 Baclofen, however, is not 
considered an ideal drug due to poor therapeutic qualities, including a narrow therapeutic 
window, low brain accumulation, quick metabolism, and rapid development of drug 
tolerance.8 This project focuses on developing novel agonists selective to the GABAB 
receptor that will overcome some of the existing deficiencies of baclofen. One way that 
has been proven to improve drug characteristics is the addition of a fluorine atom.6 
                               Figure 2 Structure of baclofen 
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1.4 Benefits of Fluorine Addition in Pharmaceuticals 
The addition of a fluorine atom in pharmaceuticals is growing due to its beneficial 
effects. Around 25% of drugs on the market are fluorinated. Fluorine is a unique atom 
because it has a high ionization energy, or the kinetic energy it takes to remove an 
electron from the outermost orbital of a fluorine atom, proving its tendency to remain 
stable. It also is the most electronegative atom on the periodic table.  
Drugs must proceed through all phases of pharmacokinetics, including absorption, 
distribution, metabolism, and excretion. Compounds that contain fluorine have been 
shown to have higher efficacy to receptors and improved lipophilicity, making it easier to 
diffuse through the nonpolar lipid membranes of cells to exhibit the desired response. 
This leads to an increase in molecular absorption. A drug with improved characteristics 
and lipophilicity can increase the bioavailability of the drug.  
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2. Results and Discussion 
2.1 Synthesis of Aromatic Difluorinated Ketones 
Agonists bind to receptors through physical and chemical interactions. 
Developing new agonists to a receptor involves some knowledge of how that receptor 
binds to endogenous and/or synthetic compounds. An “active-site” is the part of a 
receptor that interacts with a molecule or ligand. The GABAB receptor has three known 
active-sites that are amino acid residues. These residues, Ser246, Tyr366, and Asp471, 
have shown binding activity with baclofen.7 
Specifically, the interaction of the carboxylate in baclofen and the Ser246 residue 
presented promise for the conformation of α-fluorinated ketones to successfully interact 
with the GABAB receptor. The discovery of a novel method to synthesize α,α-
difluorinated ketones was a driving force for evaluation of these specific ketones as 
agonists to GABAB. A desirable property of α,α-difluorinated, or difluoromethyl, ketones 
includes the ability to convert to a hydrate, or gem diol, in water due the presence of the 
two electron-withdrawing fluorine atoms, which in turn changes the three-dimensional 
conformation and increases the aqueous solubility of the compound.7 Previous 
investigations into difluoromethyl ketones as GABAB agonists have shown implications 
of the ketones in serving as potent agonists of GABAB with selectivity over GABAA.7 A 
selection of three difluoromethyl ketones paired from three unique aldehydes (Figure 3) 
were synthesized in this project using a novel method for trifluoroacetate release and 
subsequent aldol addition.
  6 
Figure 3 Synthesis of aromatic difluorinated ketones 
The novel method of synthesis using trifluoroacetate release, discovered in the 
Colby laboratory, uses a commercially available starting material, a type of 1,1,1-
trifluoro-2,4-dione, existing in the enol form.8 The dione used for this project was (Z)-
4,4,4-trifluoro-3-hydroxy-1-(naphthalen-2-yl)-but-2-en-1-one and was reacted with a 
fluorinating agent, Selectfluor, under anhydrous conditions to yield the desired α,α-di-
fluorinated ketone (Figure 4). This reaction used mild conditions and is applicable with 
many substrates.8 This project capitalized on this synthetic method to use the generated 
ketone (2,2,4,4,4,-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)-butan-1-one) as a 
scaffold to produce unique ketones with varying aromatic functional groups by aldol 
reactions. The products were analyzed and yield values were obtained and reported (see 
experimental details). 
Figure 4 Fluorination of starting material 
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2.2 Synthesis of Aromatic Monofluorinated Ketones 
This project also produced the monofluorinated analogues for side-by-side 
comparison to each of the aromatic difluorinated ketones at the GABAB receptor. 
Synthesizing the monofluorinated ketones involved similar reaction methods and the 
same three aldehydes. In order to produce the scaffold (2,4,4,4-tetrafluoro-3,3-dihydroxy-
1-(naphthalen-2-yl)-butan-1-one) for monofluorinated ketones, the reaction was run with 
Selectfluor in the presence of water, rather than under anhydrous conditions stated 
previously (Figure 5). These reactions also needed a lower temperature in order to react 
successfully rather than room temperature for the difluorinated counterparts. Also, the 
monofluorinated reaction using 4-acetylbenzaldehyde, was purified with a preparative 
TLC plate after failing to purify using flash chromatography. The yield for compound 4 
and its 1H NMR spectra were not obtained for this report due to the restrictions on 
laboratory access after COVID-19 pandemic in the spring of 2020.
 
Figure 5 Synthesis of monofluorinated ketones 
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2.3 Compound Analysis and Purification Methods 
To purify the compounds produced in this project, the main procedure used was 
silica flash chromatography, or column purification. For this method, a solvent system is 
chosen that will be able to load the product onto silica and separate the desired compound 
from impurities or side products. The idea of column purification is that the different 
compounds present in the crude mixture will separate in the solvent system, move 
through the silica, and flow out of the gel at different rates according to the polarity of 
each compound in the mixture. The solvent system used in previous literature helped set 
a baseline for solvent system testing. To help pick a solvent system that would work best 
for each specific product, thin layer chromatography or TLC plates were used. The crude 
compound was spotted onto a TLC plate and placed in a small amount of solvent system. 
The plate was later analyzed to see which solvent system had the best separation of 
product.  
To analyze the structure of the product, nuclear magnetic resonance imaging was 
used. Both proton and fluorine NMR spectra were taken for each product. Spectra were 
analyzed in order to deduce the structure of the products of each reaction by using key 
expected peaks as well as to visualize if any side products or impurities were still present 
in the product mixture. Fluorine NMR was especially important in order to ensure 
monofluorination instead of difluorination of the products. Purity and confirmation of 
structure are both important to document prior to the acquisition of biological data for the 
compounds. Some NMR spectra collected may be inclusive on the complete purity of 
compounds found in the product, as well as the presence of both fluorinations in the same 
mixture. Also, racemic mixtures were not separated as a part of this project.   
  9 
2.4 Future Biological Analysis  
The molecules synthesized in this project are to be submitted for biological 
evaluation at the GABAB receptor for activity and potency similar to previously 
investigated difluoromethyl ketones. Prior research into the evaluation of difluoromethyl 
ketones, baclofen, and GABA was performed to quantify activity as agonists at both the 
GABAB and GABAA receptors (Table 1).7 Dose response curves and EC50 values, which 
measure compound potency, were obtained in previous studies. The ketones were found 
to be agonists at the GABA receptor, with less potency than GABA and baclofen, but 
were selective to GABAB over GABAA.  
Other data gathered included behavioral rodent assays. These assays tested plain 
acoustic startle and fear-potentiated startle and can be a measure of the potential for a 
compound to progress into a drug that can treat an anxiety disorder, including those 
effects associated with addiction.7 Later, data will be quantified in order to compare 
activities and differentiate potency between monofluorination and difluorination. No data 
has been received of the compounds synthesized in this project at this time.   
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Table 1 GABAB and GABAA Assay Data 
Compound GABAB EC50 (µM)a GABAA EC50 (µM)a 
Source: Han, C.; Salyer, A.E.; Kim, E. H.; Jiang, H.; Jarrard, R.E.; Powers, M.S.; Kirchoff, 
A.M.; Salvador, T.K.; Chester, J.A.; Hockerman, G.H.; Colby, D.A. Evaluation of 
Difluoromethyl Ketones as Agonists of the 𝛾-Aminobutryic Acid Type B (GABAB) Receptor. 
Med. Chem. 2013, 56, 2456–2465 
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3. Conclusion 
In conclusion, this project involved the synthesis of six aromatic fluorinated 
ketones. Three of the ketones were difluorinated, and the other three ketones were the 
monofluorinated analogue of each. Each compound was synthesized using 
trifluoroacetate release, purified by either silica flash chromatography or preparative 
TLC, and analyzed with nuclear magnetic resonance. All products will be sent for 
biological evaluation at the GABAB receptor, where potency will be measured as well as 
potency differentials between fluorinations.
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4. Experimental Details 
2,2,Difluoro-3-hydroxy-3-(4-methoxyphenyl)-1-(naphthalen-2-yl)-propan-1-one, 1. 
Both LiBr (40.4 mg, 0.4650 mmol), and 𝑝-anisaldehyde (38.0 µL, 0.3122 mmol), were 
added to a solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)-butan-1-
one (50 mg, 0.16 mmol) dissolved in THF (1 mL). Et3N (22.0 µL, 0.16 mmol) was added 
dropwise to the mixture, and the reaction was stirred for 3 min at rt. After 3 min, the 
reaction was quenched with NH4Cl (3 mL). The resulting mixture was extracted with 
EtOAc (3 mL ⨉ 3). The organic layer was dried over Na2SO4 and concentrated under 
reduced pressure. SiO2 flash chromatography (8.5:1.5 hexanes/EtOAc) was performed 
and afforded the product with 43% yield: 1H NMR (500 MHz, CDCl3) 𝛿 8.62 (s, 5H), 
8.25 (d, J = 9.5 Hz, 2H), 8.03–7.86 (m, 12H), 7.66 (t, J = 20 Hz, 4H), 7.58 (t, J = 20 Hz, 
4H), 7.46 (d, J = 20 Hz, 8H), 3.81 (s, 15H); 19F NMR (500 MHz, CDCl3) 𝛿 –105 (dd, J = 
390 Hz, 1F), –116 (dd, J = 405 Hz, 1F). 
3-(4-Acetylphenyl)-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)-propan-1-one, 2. 
Both LiBr (71.2 mg, 0.82 mmol), and 4-acetylbenzaldehyde (83.7 mg, 0.5652 mmol), 
were added to a solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)-
butan-1-one (90.5 mg, 0.283 mmol) dissolved in THF (1.8 mL). Et3N (39.0 µL, 0.283 
mmol) was added dropwise to the mixture, and the reaction was stirred for 24 hr at rt. 
After 24 hr, the reaction was quenched with NH4Cl (6 mL). The resulting mixture was 
extracted with EtOAc (6 mL ⨉ 3). The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. SiO2 flash chromatography (8:2 hexanes/EtOAc) 
was performed and afforded the product with 16% yield: 1H NMR (500 MHz, CDCl3) 𝛿 
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8.66 (s, 1H), 8.07 (d, J = 10 Hz, 1H), 8.00 (d, J = 5 Hz, 2H), 7.95–7.88 (m, 3H), 7.66 (d, 
J = 10 Hz, 3H), 7.57 (t, J = 15 Hz, 1H), 5.54 (d, J = 15 Hz, 1H), 2.62 (s, 3H); 19 NMR 
(500 MHz, CDCl3) 𝛿 –103 (d, J = 5 Hz, 1F), –104 (d, J = 5 Hz, 1F). 
3-(Benzo[d][1,3]dioxol-5-yl)-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)-propan-1-
one, 3. Both LiBr (160 mg, 1.8 mmol), and benzo[d][1,3]dioxole-5-carbaldehyde (65.6 
mg, 0.437 mmol), were added to a solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalen-2-yl)-butan-1-one (70.0 mg, 0.22 mmol) dissolved in THF (1.4 mL). Et3N 
(30.5 µL, 0.22 mmol) was added dropwise to the mixture, and the reaction was stirred for 
24 hr at rt. Next, the reaction was quenched with NH4Cl (5 mL). The resulting mixture 
was extracted with EtOAc (6 mL ⨉ 3). The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. SiO2 flash chromatography (7:3 hexanes/EtOAc) 
was performed and afforded the product with 34% yield: 1H NMR (500 MHz, CDCl3) 𝛿 
8.64 (s, 1H), 8.06 (d, J = 10 Hz, 1H), 7.95–7.87 (m, 4H), 7.61 (dt, J = 50 Hz, 3H), 7.06 
(s, 1H), 6.98 (d, J = 10 Hz, 1H), 6.83 (d, J = 10 Hz, 3H), 5.97 (d, J = 5 Hz, 3H), 5.35 (dt, 
J = 30 Hz, 2H), 3.07 (d, J = 5 Hz, 1H); 19F NMR (500 MHz, CDCl3) 𝛿 –105 (dd, J = 315 
Hz, 1F), –116 (dd, J = 325 Hz, 1F). 
 
2-Fluoro-3-hydroxy-3-(4-methoxyphenyl)-1-(naphthalen-2-yl)-propan-1-one), 4. 
Both LiBr (97.5 mg, 1.12 mmol), and 𝑝-anisaldehyde (57.0 µL, 0.468 mmol), were added 
to a solution of 2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)-butan-1-one (100.0 
mg, 0.312 mmol) dissolved in THF (2.0 mL). Et3N (0.2 mL, 1.2 mmol) was added 
dropwise to the mixture, and the reaction was stirred for 24 hr at 0°C. Next, the reaction 
was quenched with NH4Cl (5 mL) and washed with H2O (5 mL). The resulting mixture 
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was extracted with EtOAc (5 mL ⨉ 3). The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. SiO2 flash chromatography (7:3 hexanes/EtOAc) 
was performed and afforded the product with an undetermined yield: 19F NMR (400 
MHz, CDCl3) 𝛿 –202 (dd, J = 1165 Hz, 1F).  
 
3-(4-Acetylphenyl)-2-fluoro-3-hydroxy-1-(naphthalen-2-yl)-propan-1-one, 5.  Both 
LiBr (97.5 mg, 1.123 mmol), and 4-acetylbenzaldehyde (70.0 mg, 0.47 mmol), were 
added to a solution of 2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)-butan-1-one 
(100.0 mg, 0.312 mmol) dissolved in THF (2.0 mL). Et3N (0.17 mL, 1.25 mmol) was 
added dropwise to the mixture, and the reaction was stirred for 24 hr at –78°C. Next, the 
reaction was quenched with NH4Cl (5 mL) and washed with H2O (5 mL). The resulting 
mixture was extracted with EtOAc (5 mL ⨉ 3). The organic layer was dried over Na2SO4 
and concentrated under reduced pressure. SiO2 flash chromatography (10:1 
dichloromethane/ether) was performed and afforded the product with a 14% yield: 1H 
NMR (400 MHz, CDCl3) 𝛿 8.43 (d, J = 32 Hz, 1H), 7.94 (d, J = 8 Hz, 2H), 7.87 (t, J = 12 
Hz, 2H), 7.59 (dt, J = 40 Hz, 3H), 5.30 (s, 1H), 4.12 (q, J = 16 Hz, 2H), 3.74 (s, 2H), 2.04 
(s, 3H), 1.26 (s, 4H); 19F NMR (400 MHz, CDCl3) 𝛿 –188 (dd, J = 52 Hz, 1F), –197 (dd, 
J = 60 Hz, 1F). 
 
3-(Benzo[d][1,3]dioxol-5-yl)-2-fluoro-3-hydroxy-1-(naphthalen-2-yl)-propan-1-one, 
6. Both LiBr (97.5 mg, 1.123 mmol), and benzo[d][1,3]dioxole-5-carbaldehyde (70.3 mg, 
0.47 mmol), were added to a solution of 2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-
2-yl)-butan-1-one (100.0 mg, 0.312 mmol) dissolved in THF (2.0 mL). Et3N (0.2 mL, 
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1.25 mmol) was added dropwise to the mixture, and the reaction was stirred for 24 hr at –
78°C. Next, the reaction was quenched with NH4Cl (5 mL) and washed with H2O (5 mL). 
The resulting mixture was extracted with EtOAc (5 mL ⨉ 3). The organic layer was dried 
over Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (10:1 
dichloromethane/methanol) was performed and afforded the product with a 21% yield: 
1H NMR (400 MHz, CDCl3) 𝛿 8.41 (d, J = 80 Hz, 1H), 7.97–7.87 (m, 5H), 7.61 (dt, J = 
48 Hz, 2H), 6.98 (d, J = 12 Hz, 1H), 6.89 (t, J = 12 Hz, 1H), 6.75 (dd, J = 28 Hz, 1H), 
5.91 (d, J = 16 Hz, 2H), 5.66 (dd, J = 44 Hz, 1H), 5.30 (s, 1H), 3.73 (s, 1H), 1.60 (t, J = 
236 Hz, 10H); 19F NMR (500 MHz, CDCl3) 𝛿 –189 (dd, J = 48 Hz, 4F), –195 (dd, J = 56 
Hz, 1F). 
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